Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford, in a new industry partnership with Axol Bioscience of Cambridge, have secured funding from the BBSRC to collaborate in creating human models of the cerebellum with induced pluripotent stem cells (iPSCs) for studies of neurological disorders.

Human iPSC-derived neurons in culture. Image courtesy of Esther Becker

Neurological disorder-associated deaths have increased by 39% in the UK since 200, with over 10 million people living with a neurological condition that has a significant impact on their lives. Due to a lack of translatable models that provide an accurate basis to study neurological disorders in humans, developing new treatments and therapies for these conditions is challenging. However, this could soon change.

“This [collaboration] allows us for the first time to study developing human nerve cells in the laboratory and to coax them into forming a brain-like structure. In our case, we plan to instruct the human iPSCs to organize into a cerebellum-like tissue”, explained Esther Becker, Associate Professor in Neurobiology at the University of Oxford.

“I’m very excited to be working together with Axol on this project. It will allow us to take advantage of their expertise in the iPSC field and it will accelerate the future applications of our research”, said Professor Becker.

Professor Becker made the BBSRC joint-funding application earlier this year after being introduced to Axol Bioscience, a biotech firm who specialise in human cell culture technologies, through IN-PART’s matchmaking platform for university-industry collaboration.

The Oxford-Axol collaboration has been awarded BBSRC funding in the form of an iCASE studentship, a joint-managed PhD project that will develop a reproducible method for generating specific and mature subpopulations of human cerebellar neurons in the lab.

“This research is of great value to the scientific community as there is a need for relevant translatable models in which to test and develop drugs for CNS [central nervous system] disorders”, said Yichen Shi, CEO and Co-founder of Axol Bioscience.

“Current models that are used during drug development tend to be immortalized cell lines or animals, both of which do not fully represent human cell phenotypes or disease”, added Yichen.

The majority of new candidate drugs developed to treat neurological disorders fail in Phase II and III clinical trials, with very few making it to Phase IV approval.

What’s more, in recent years there have been significant project shutdowns and facility closures in the neuroscience wings of the pharmaceutical industry. This is thought to be due to safety issues, low success rates, and increasing R&D costs.

The goal of the Oxford-Axol collaboration will be to model aspects of human cerebellar development that could in the future be used as platforms for the screening of future therapeutic treatments. The OxfordAxol researchers will carry out extensive studies into brain development, as well as the molecular and cellular processes that go wrong in central nervous system diseases.

“It’s fantastic to see that the iCASE studentship was awarded. I look forward to seeing how the project develops and hope this is the start of a great relationship between the two institutes,” said Dr. Siobhan Dennis, Industry Partnerships Manager at the University of Oxford.

“This was a completely new interaction and one that would not have occurred without the project being presented on IN-PART”, added Dr. Dennis.

The successful PhD candidate will benefit from the Oxford Interdisciplinary Bioscience Doctoral Training Partnership (DTP) core skills and career development training while spending time in the Becker lab and during their industrial placement at Axol Bioscience’s labs in Cambridge.

Article and image credit: Alex Stockham, IN PART Communications Manager 

For further information or to find out how to engage with IN PART, please contact Dr Siobhan Dennis (siobhan.dennis@medsci.ox.ac.uk)

Similar stories

Oxford spin-out Optellum attains CE marking for its early lung cancer diagnosis AI technology

The contribution of individual features on clinical imaging scans to the performance of the LCP-CNN cancer risk prediction model developed in Oxford was investigated.

Oxford University retains top spot for spinout generation in the UK

Oxford University has been ranked first in the UK for turning academic research into spinout companies, according to a new report published today by data analyst firm Beauhurst.

The glass half full man: Professor Chas Bountra and Oxford's innovative future

Forget the TV clichés about Oxford – all punting and pass the port. The 925-year-old university is full of the most amazing people who are helping and benefiting the world, well beyond the quads and spires, says Professor Chas Bountra, the university’s Pro-Vice-Chancellor for Innovation. After the events of the last two years - and the COVID-19 vaccine [2.5 billion doses delivered and counting] - this most enthusiastic champion of Oxford maintains there can be no doubt, innovation is part and parcel of the historic university’s future. Who knows what is coming next, he says, expectantly.

Exscientia and University of Oxford launch “Xcellomics” program to expedite early-stage academic research and translate novel biology into future drug discovery

Exscientia and the University of Oxford's Target Discovery Institute (TDI) today announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.

Professor Collins awarded Sir Jules Thorn Translational Biomedical Research Award 2021

Professor Sally Collins has been awarded the prestigious and highly competitive Sir Jules Thorn Translational Biomedical Research Award 2021 for further translational development of the OxNNet Toolkit.

Sir Jon Symonds joins Pharmacology as a Visiting Fellow

The Department of Pharmacology is delighted to announce the appointment of Sir Jonathan Symonds CBE, Chair of the Board of GlaxoSmithKline, as a Visiting Fellow. Jon has been Chairman of the Board at GSK since September 2019.